Dermapharm Holding SE (ETR:DMP)

Germany flag Germany · Delayed Price · Currency is EUR
35.15
+0.90 (2.63%)
Aug 27, 2025, 1:44 PM CET
2.63%
Market Cap1.84B
Revenue (ttm)1.20B
Net Income (ttm)107.20M
Shares Out53.84M
EPS (ttm)1.99
PE Ratio17.18
Forward PE13.95
Dividend0.90 (2.63%)
Ex-Dividend DateJun 27, 2025
Volume17,823
Average Volume19,906
Open34.00
Previous Close34.25
Day's Range33.65 - 35.40
52-Week Range30.15 - 42.50
Beta1.28
RSI57.01
Earnings DateAug 26, 2025

About Dermapharm Holding SE

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as product... [Read more]

Sector Healthcare
Founded 1991
Employees 3,610
Stock Exchange Deutsche Börse Xetra
Ticker Symbol DMP
Full Company Profile

Financial Performance

In 2024, Dermapharm Holding SE's revenue was 1.20 billion, an increase of 3.89% compared to the previous year's 1.15 billion. Earnings were 113.79 million, an increase of 82.44%.

Financial Statements

News

Dermapharm's Steady Growth: H1 Stability & Q2 EBITDA Boost

Dermapharm's strategic maneuvers in H1 2025 underscore its adaptability, with branded pharmaceuticals thriving amid a minor revenue decline, setting a promising tone for the year's financial outlook. ...

1 day ago - Wallstreet:Online

EQS-News: Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter

EQS-News: Dermapharm Holding SE / Key word(s): Half Year Report/Half Year Results Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter 2...

1 day ago - Wallstreet:Online

EQS-AFR: Dermapharm Holding SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

EQS Preliminary announcement financial reports: Dermapharm Holding SE / Preliminary announcement on the disclosure of financial statements Dermapharm Holding SE: Preliminary announcement of the public...

9 days ago - Wallstreet:Online

Dermapharm Holding SE: On Track for Growth in Q2 2025!

Dermapharm Holding SE remains steadfast in its 2025 financial goals, leveraging robust growth in branded pharmaceuticals to offset challenges in other sectors. Jetzt den vollständigen Artikel lesen

15 days ago - Wallstreet:Online

EQS-News: Dermapharm Holding SE remains on projected growth trajectory in Q2 2025

EQS-News: Dermapharm Holding SE / Key word(s): Half Year Results/Preliminary Results Dermapharm Holding SE remains on projected growth trajectory in Q2 2025 12.08.2025 / 07:30 CET/CEST The issuer is s...

15 days ago - Wallstreet:Online

EQS-DD: Dermapharm Holding SE: Wilhelm Beier, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 04.07.2025 / 16:17 CET/CEST The issuer is solely responsi...

7 weeks ago - Wallstreet:Online

EQS-DD: Dermapharm Holding SE: Dr. Andreas Eberhorn, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 24.06.2025 / 16:45 CET/CEST The issuer is solely responsi...

2 months ago - Wallstreet:Online

EQS-DD: Dermapharm Holding SE: Anja Schorn, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 05.06.2025 / 12:28 CET/CEST The issuer is solely responsi...

2 months ago - Wallstreet:Online

EQS-DD: Dermapharm Holding SE: Dr. Hans-Georg Feldmeier, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 04.06.2025 / 11:18 CET/CEST The issuer is solely responsi...

3 months ago - Wallstreet:Online

Dermapharm Hits Q1 Targets, Reaffirms 2025 Outlook

Dermapharm Holding SE's Q1 2025 results align with expectations, driven by strong growth in key segments, despite some challenges, and affirming their full-year guidance. Jetzt den vollständigen Artik...

3 months ago - Wallstreet:Online

EQS-PVR: Dermapharm Holding SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Voting Rights Announcement: Dermapharm Holding SE Dermapharm Holding SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wid...

4 months ago - Wallstreet:Online

EQS-DD: Dermapharm Holding SE: Susanne Gertrud Pia Lanz, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 08.04.2025 / 16:43 CET/CEST The issuer is solely responsi...

5 months ago - Wallstreet:Online

Dermapharm's 2024: Revenue Soars, Surpassing EBITDA Expectations

Dermapharm's financial results for 2024 reflect a dynamic year of growth and strategic adjustments, setting a promising stage for the future. Jetzt den vollständigen Artikel lesen

5 months ago - Wallstreet:Online

EQS-News: Successful financial year 2024: Dermapharm increases revenue and exceeds EBITDA guidance

EQS-News: Dermapharm Holding SE / Key word(s): Annual Results/Annual Report Successful financial year 2024: Dermapharm increases revenue and exceeds EBITDA guidance 28.03.2025 / 07:30 CET/CEST The iss...

5 months ago - Wallstreet:Online

EQS-DD: Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 18.03.2025 / 13:12 CET/CEST The issuer is solely responsi...

5 months ago - Wallstreet:Online

Dermapharm Surpasses EBITDA Forecast with Revenue Boost

Dermapharm Holding SE's financial prowess shines with a 4% revenue boost, driven by 'Branded pharmaceuticals,' and a 10.2% EBITDA surge, setting the stage for promising growth in 2025. Jetzt den volls...

5 months ago - Wallstreet:Online

EQS-News: Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA

EQS-News: Dermapharm Holding SE / Key word(s): Annual Results/Preliminary Results Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA 14.03.2025 ...

5 months ago - Wallstreet:Online

EQS-DD: Dermapharm Holding SE: Wilhelm Beier, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 30.12.2024 / 12:38 CET/CEST The issuer is solely responsi...

8 months ago - Wallstreet:Online

EQS-DD: Dermapharm Holding SE: Dr. Hans-Georg Feldmeier, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 11.11.2024 / 16:30 CET/CEST The issuer is solely responsi...

10 months ago - Wallstreet:Online

EQS-DD: Dermapharm Holding SE: Christof Dreibholz, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 05.11.2024 / 15:12 CET/CEST The issuer is solely responsi...

10 months ago - Wallstreet:Online

Dermapharm Holding SE: High-Margin Pharma Boosts Global Organic Growth

Dermapharm Holding SE showcases robust organic growth in its branded pharmaceuticals segment, offsetting a revenue dip from the cessation of pandemic-related vaccine production. Unadjusted EBITDA surg...

1 year ago - Wallstreet:Online

EQS-News: Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies

EQS-News: Dermapharm Holding SE / Key word(s): Half Year Results/Half Year Report Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at Germa...

1 year ago - Wallstreet:Online

Dermapharm Holding: Thriving on High-Margin Organic Growth in Pharma Business

Despite a slight dip in overall revenue and earnings, strong performance in branded pharmaceuticals has helped Dermapharm navigate the post-pandemic landscape. The company remains optimistic about its...

1 year ago - Wallstreet:Online

EQS-News: Sustained organic growth in high-margin existing branded pharmaceutical business

EQS-News: Dermapharm Holding SE / Key word(s): Half Year Results/Preliminary Results Sustained organic growth in high-margin existing branded pharmaceutical business 14.08.2024 / 07:30 CET/CEST The is...

1 year ago - Wallstreet:Online